Skip to main content
Journal cover image

Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.

Publication ,  Journal Article
Haze, T; Hirawa, N; Yano, Y; Tamura, K; Kurihara, I; Kobayashi, H; Tsuiki, M; Ichijo, T; Wada, N; Katabami, T; Yamamoto, K; Oki, K; Kai, T ...
Published in: Atherosclerosis
May 2021

BACKGROUND AND AIMS: We used a dataset from a Japanese nationwide registry of patients with primary aldosteronism, to determine which of the parameters of hyperaldosteronism and blood pressure before or after treatments for primary aldosteronism (i.e., surgical adrenalectomy or a medication treatment) are important in terms of cardiovascular prognosis. METHODS: We assessed whether plasma aldosterone-to-renin ratio and pulse pressure levels before treatment and 6 months after treatment were associated with composite cardiovascular disease events during the 5-year follow-up period. RESULTS: The cohort included 1987 patients (mean age was 53.2 years, 52.0% were female, 37.2% had undergone surgical treatment, and the remainder had been treated with mineralocorticoid receptor antagonists). In the Cox proportional hazard model, the covariate-adjusted hazard ratio (95% confidence interval) for the composite cardiovascular disease events risk for each one-standard-deviation increase in the aldosterone-to-renin ratio or pulse pressure before treatment, those after treatment, or the duration of hypertension were 1.24 (1.05, 1.48), 0.74 (0.54, 1.02), and 1.07 (0.79, 1.44), 1.43 (1.07, 1.92), and 1.52 (1.19, 1.95), respectively. Patients with a high pre-treatment aldosterone-to-renin ratio of more than 603 and a large post-treatment pulse pressure of more than 49 mmHg showed approximately three-fold higher hazard ratios for cardiovascular events risk compared to those with a lower aldosterone-to-renin ratio and smaller pulse pressure. CONCLUSIONS: Higher aldosterone-to-renin ratio before treatments, higher pulse pressure after treatments, and longer duration of hypertension were prognostic factors for cardiovascular diseases. Early intervention may be important for preventing cardiovascular disease among patients with primary aldosteronism.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Atherosclerosis

DOI

EISSN

1879-1484

Publication Date

May 2021

Volume

324

Start / End Page

84 / 90

Location

Ireland

Related Subject Headings

  • Mineralocorticoid Receptor Antagonists
  • Middle Aged
  • Male
  • Hypertension
  • Hyperaldosteronism
  • Humans
  • Female
  • Cardiovascular System & Hematology
  • Cardiovascular Diseases
  • Blood Pressure
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haze, T., Hirawa, N., Yano, Y., Tamura, K., Kurihara, I., Kobayashi, H., … Naruse, M. (2021). Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism. Atherosclerosis, 324, 84–90. https://doi.org/10.1016/j.atherosclerosis.2021.03.033
Haze, Tatsuya, Nobuhito Hirawa, Yuichiro Yano, Kouichi Tamura, Isao Kurihara, Hiroki Kobayashi, Mika Tsuiki, et al. “Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.Atherosclerosis 324 (May 2021): 84–90. https://doi.org/10.1016/j.atherosclerosis.2021.03.033.
Haze T, Hirawa N, Yano Y, Tamura K, Kurihara I, Kobayashi H, et al. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism. Atherosclerosis. 2021 May;324:84–90.
Haze, Tatsuya, et al. “Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.Atherosclerosis, vol. 324, May 2021, pp. 84–90. Pubmed, doi:10.1016/j.atherosclerosis.2021.03.033.
Haze T, Hirawa N, Yano Y, Tamura K, Kurihara I, Kobayashi H, Tsuiki M, Ichijo T, Wada N, Katabami T, Yamamoto K, Oki K, Inagaki N, Okamura S, Kai T, Izawa S, Yamada M, Chiba Y, Tanabe A, Naruse M. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism. Atherosclerosis. 2021 May;324:84–90.
Journal cover image

Published In

Atherosclerosis

DOI

EISSN

1879-1484

Publication Date

May 2021

Volume

324

Start / End Page

84 / 90

Location

Ireland

Related Subject Headings

  • Mineralocorticoid Receptor Antagonists
  • Middle Aged
  • Male
  • Hypertension
  • Hyperaldosteronism
  • Humans
  • Female
  • Cardiovascular System & Hematology
  • Cardiovascular Diseases
  • Blood Pressure